UK inflation unexpectedly eases in December, which could reduce pressure in bond markets
Body count from South African mine siege rises to 60
US importers rush in goods from China as Trump tariff threat looms
Novak Djokovic breaks a tie with Roger Federer for the most Grand Slam matches in tennis history
China's RedNote: what you need to know about the app TikTok users are flocking to
British author Neil Gaiman denies ever engaging in non-consensual sex as more accusers come forward
(Reuters) -Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United States, EU and Japan.
The collaboration will help Bristol Myers to expand its manufacturing capacity due to increasing demand. The company said in February it was looking to launch both its CAR-T blood cancer therapies Abecma and Breyanzi in a number of new countries this year.
CAR-T therapy involves removing a patients' own T cells - a key component of the immune system - engineering them to recognize and attack malignant cells, and re-infusing them.
(Reporting by Christy Santhosh; Editing by Shinjini Ganguli)
